GLP-1 Drugs and Type 1 Diabetes: What the Evidence Shows So Far

Over the past 20 years, a class of medications called incretin-based therapies has revolutionized diabetes care. The most well-known are GLP-1 receptor agonists—drugs like semaglutide and exenatide—and newer combinations that also target a hormone called GIP. These medications were designed to help the body manage blood sugar more effectively.

In type 2 diabetes, these drugs have delivered significant benefits: they help people lose weight, reduce insulin resistance, improve blood sugar control, and lower risk markers for kidney disease and heart disease. Since exenatide was approved in 2005, the number of available options has grown substantially, and regulatory agencies have approved them for type 2 diabetes, obesity, sleep apnea, and certain liver conditions.

Type 1 diabetes is different from type 2 in a fundamental way: the immune system attacks insulin-producing cells, so people with type 1 require insulin from day one. This raises the question: could GLP-1 drugs help type 1 patients better manage their condition alongside insulin?

The short answer is: we don't know yet. While some people with type 1 are already using these medications outside of official approval, the scientific evidence is limited. The studies conducted so far have been small, inconsistent in their findings, and based on real-world experience rather than large controlled trials. Regulators have not approved GLP-1 or GLP-1/GIP drugs specifically for type 1 diabetes, in large part because this evidence gap exists.

Because type 1 diabetes involves insulin dependence, adding a new medication requires special caution. Experts have identified two significant safety risks when starting GLP-1 or GLP-1/GIP drugs in people with type 1:

The first is hypoglycemia—dangerously low blood sugar. These drugs can lower glucose levels, which combined with insulin therapy could create a serious risk. The second is a metabolic emergency called ketosis, where the body produces high levels of acids called ketones. This can happen early after starting these medications and is a particular concern in type 1 diabetes.

Because of these risks, any use of GLP-1 or GLP-1/GIP drugs in type 1 diabetes requires close medical supervision and careful insulin adjustment.

The diabetes research community recognizes both the potential benefit and the knowledge gap. Larger, more rigorous clinical trials are currently underway or in the planning stages specifically to test whether GLP-1 and GLP-1/GIP receptor agonists are safe and effective when used alongside insulin in type 1 diabetes.

These studies will help determine whether these medications can be a useful tool for type 1 patients, what doses are appropriate, how to manage the safety risks, and which patients might benefit most. Until that evidence is solid, any use remains experimental and should only happen under close medical guidance with specialized expertise in type 1 diabetes management.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.